The Saos-2, U2OS and HEK-293T human OS cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in Dulbecco's modified Eagle's medium (GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (GE Healthcare Life Sciences), 100 units of penicillin/streptomycin (Invitrogen Life Technologies, Carlsbad, CA, USA) and maintained at 37°C in air with a 5% CO₂ humidified atmosphere.

The 30 OS samples and their adjacent healthy tissues were obtained from the surgical specimens of patients treated in Yuhuangding Hospital of Yantai (Yantai, China). Written informed consent was obtained from the patient. The samples were selected from patients with complete clinicopathologic information, who had been diagnosed and treated between June 2009 and November 2013. Of the 30 cases, there were 17 males and 13 females aged between 32 and 70 years (median, 55.3 years). The study was approved by the ethics committee of Qingdao University Medical College (Yantai, China). All patients were followed up for survival. The survival time was followed up from the diagnosis date up until cancer-associated death every 6 months. Only 2 patients were excluded from the study due to loss of contact, therefore these two cases were excluded from the statistical analysis (n=28).

Total cellular RNA was isolated from the Saos-2 cells using TRIzol reagent and amplified using an RT-qPCR kit (Invitrogen Life Technologies). The first strand of cDNA was synthesized using 1 µg total RNA with M-MLV Reverse Transcriptase and the following primers were used for the detection of Plk3: Forward, 5-TCTGTTTGCCAAAGTTACCA-3 and reverse, 5-TTCTTCAAATCCATCTCCACTG-3. β-actin served as the internal control and was amplified using the following primers: Forward, 5-GTGGACATCCGCAAAGAC-3 and reverse, 5-AAAGGGTGTAACGCAACTA-3. qPCR was conducted using an ABI PRISM^® 7500 sequence detection system (Applied Biosystems Life Technologies, Foster City, CA, USA) and the relative expression levels of Plk3 in non-transduced and transduced Saos-2 cells were determined. The cycling conditions were as follows: 93°C for 2 mins, (93°C for 1 min, 55°C for 1 min, 72°C for 1 min, 40 cycles) 72°C for 10 min, then held at 4°C. A Plk3 plasmid was generated by inserting a full length of Plk3 into a pCMV-Tag2B vector (Invitrogen Life Technologies).

Non-transduced and transduced Saos-2 cells were lysed in 50 ml lysis buffer (100 mM Tris-HCl (pH 7.4), 10 mM EDTA, 4% SDS and 10% glycine) on ice for 45 min. The supernatants were collected by centrifugation at 12,000 × g for 30 min at 4°C, and performance of a bicin-choninic acid method determined the protein concentration (BCA kit; GE Healthcare Life Sciences). Equal quantities (30 µg protein) of lysate were run on 10% SDS-PAGE gels (Invitrogen Life Technologies). Following electrophoresis, the protein blots were transferred onto nitrocellulose membranes (GE Healthcare Life Sciences) using electroblotting apparatus (Bio-Rad Mini-PROTEAN Tetra Electrophoresis system, Bio-Rad Laboratories, Inc., Hercules, CA, USA) and were then blocked with 5% non-fat milk in Tris-buffered saline and Tween-20 (TBST) solution (Sigma-Aldrich, St. Louis, MO, USA). The membrane was incubated overnight with rabbit anti-Plk3 antibody (cat. no. SAB1300123), which was obtained from Sigma-Aldrich (dilution, 1:1,000) and rabbit anti-P21 antibody (cat. no. sc-397) obtained from Santa Cruz Biotechnology, Inc., Dallas, TX, USA; dilution, 1:500);. After three washes with TBST solution, the membrane was incubated with a secondary antibody (Santa Cruz Biotechnology, Inc.; dilution, 1:5,000) at room temperature for 60 min. Immunoreactive bands were visualized using Western Blotting Luminol Reagent (Santa Cruz Biotechnology, Inc.) according to the manufacturer's instructions. The β-actin protein level served as a control (cat. no. sc-8432; mouse IgG1; Santa Cruz Biotechnology, Inc.).

The recombinant lentivirus and lentivirus vectors containing Plk3 short hairpin (sh)RNA#1 (5-CCGGGCCCTTGCCTTTGTGGCCTTCCTCGAGGAAGGCCACAAAGGCAAGGGCTTTTTTG-3) or Plk3 shRNA#2 (5-CCGGGATTTGAAGAAGGTCTGACTGCTCGAGCAGTCAGACCTTCTTCAAATCTTTTTTG-3) were constructed and inserted into the PCMV-t green fluorescent protein (GFP) plasmid (Sigma-Aldrich). Non-silencing shRNA (5-CTAGCCCGGTTCTCCGAACGTGTCACGTATCTCGAGATACGTGACACGTTCGGAGAATTTTTTTAAT-3) served as a control, as it does not target any genes in humans. Digestion analysis using a restriction endonuclease (Beijing TransGen Biotech Co., Ltd., Beijing China) confirmed the formation of the recombinant vector and all of the inserted sequences were verified by DNA sequencing. Lentiviruses were developed by triple transfection of 80% confluent 293T cells with Plk3 shRNA-expressing vector or the control shRNA, using Lipofectamine 2000 (Invitrogen Life Technologies). The cells were harvested in serum-free medium after 3 days and filtered through a 0.45-µm filter (Merck Millipore, Bedford, MA, USA).

Transduction was conducted by seeding Saos-2 cells (5×10⁴ cells/well) in 6-well plates along with shRNA encoded recombinant lentiviruses against Plk3 (Lv-shPlk3) at a multiplicity of infection of 60 in serum-free growth medium. When serum-containing growth medium was added to the cells after 4 h, there had been complete replacement of the growth medium with recombinant lentivirus. After 3 days of transfection, expression of the reporter gene, GFP was examined using fluorescence microscopy (Olympus BX53; Olympus Corporation).

For IP assays, cells were washed with cold phosphate-buffered saline (PBS) and lysed with cold lysis buffer at 4°C for 45 min. Whole cell lysates were incubated with Plk3 or P21 antibodies or normal rabbit/mouse immunoglobulin G on a rotator (Liuyi Instrument Factory, Beijing, China), overnight at 4°C, followed by the addition of protein A/G Sepharose CL-4B beads (GE Healthcare Life Sciences) for 2 h at 4°C. The beads were then washed five times with lysis buffer [50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate and protease inhibitor mixture]. The immune complexes were subjected to SDS-PAGE, followed by immunoblotting (IB) with secondary antibodies.

Saos-2 cells stably transfected with shPlk3 or control shRNA were synchronized by serum starvation for 24 h, cells (density, >90%) were then trypsinized (Sigma-Aldrich), collected, washed with PBS and fixed in 70% ethanol at 4°C overnight. After washing with PBS, cells were incubated with RNase A (Sigma-Aldrich) in PBS for 30 min at 37°C and stained with 50 mg/ml propidium iodide (Sigma-Aldrich). Cell cycle data were collected using a FACSCalibur™ flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed with FlowJo 7.6.2 (FlowJo, LLC, Ashland, OR, USA), which was repeated three times.

Following infection with the lentivirus for 3 days, a total of 1,000 Saos-2 cells were seeded into 6-well plates, and the medium was changed at 3-day intervals. G418 was used to select the cells transfected with the recombinant lentivirus and lentivirus vectors. After 10 days of culturing, the colonies formed were washed with PBS and fixed in 4% paraformaldehyde at 37°C for 30 min, after which the colonies were stained with Coomassie (Sigma-Aldrich) for 15 min, washed and air-dried. The colonies were counted under a microscope (Olympus BX46; Olympus Corporation). This experiment was performed in triplicate.

Saos-2 cells were seeded in 6-well plates for 24 h and transfected with the indicated shRNAs using Lipofectamine 2000. After 48 h of transfection, cells were incubated with EdU (Guangzhou Ribobio, Co., Ltd., Guangzhou, China) for 4 h, fixed with 4% formaldehyde for 30 min and incubated with 2 mg/ml glycine for 5 min. The assay was performed according to the manufacturer's instructions, using a fluorescence method. Furthermore, the positive and negative controls for the EdU assay were applied according to the manufacturer's instructions. Finally, 6-diamidino-2-phenylindole (Sigma-Aldrich) was used to stain the nuclei. The Olympus BX53 was used to observe the fluorescence.

SPSS version 17.0 was used for statistical analysis (SPSS, Inc., Chicago, IL, USA). Comparisons between cancer tissue and adjacent normal tissue were performed using a paired samples t-test. P<0.05 was considered to indicate a statistically significant difference.

The expression level of Plk3 was analyzed in different OS cell lines. As shown in Fig. 1A, downregulation of Plk3 was observed in the two examined OS cell lines, Saos-2 and U2OS, when compared with the HEK293 cells; the protein levels were also detected to be deceased (Fig. 1B). In addition, the expression levels of Plk3 were examined in 30 OS samples collected at the Yuhuangding Hospital of Yantai (Yantai, China) and the paired non-cancerous tissue (NT) samples were analyzed using RT-qPCR. The results demonstrate that the mean expression levels of Plk3 in the 30 OS samples (median, 1.4250; max., 3.1859; min., −1.3429) are significantly lower than those in the pairs of adjacent non-cancerous tissue (median, −0.1489; max., 1.2074; min., −2.5398; P=0; Fig. 1C). The expression level of Plk3 decreased in the OS samples, indicating that downregulation of Plk3 may be significant in OS. The OS samples obtained from the patients were divided into two groups, high and low, based on the median Plk3 expression level. Kaplan-Meier survival analyses of the different groups (Fig. 1D) demonstrated that higher Plk3 expression was associated with a longer overall survival time for patients with OS (hazard ratio=6.09; P=0.0239).

The efficiency of the recombinant lentivirus was measured by RT-qPCR and western blotting. The mRNA expression level of shRNA-Plk3#1 was ~10% that of the control group and shRNA-Plk3#2 was ~8% of the control (P<0.001; Fig. 1E). The transfection ratio was observed to be ~100%. Western blot analysis demonstrated the protein levels (Fig. 1F) and indicated that the inhibitory ratios of shRNA-Plk3#1 and shRNA-Plk3#2 were 12.5 and 8.5%, respectively. The efficiency of the Plk3 overexpression was also detected by western blotting (Fig. 1G).

To investigate the function of Plk3 in cell proliferation, the cell cycle distribution following transfection of shRNA-Plk3#2, or the recombinant plasmid with Plk3 overexpression, was examined in Saos-2 cells by flow cytometry. Compared with mock-transfected cells, shPlk3-transfected cells revealed a substantial increase in S-phase populations and a decrease in G₁ phase populations, with Plk3 overexpression causing a block at the G₁ to S phase (Fig. 2A and B). These data indicate that inhibition of OS cell growth by Plk3 may be mediated via induction of G₁ arrest.

In order to further understand the role of Plk3 in tumorigenicity, growth assays were performed in different cell vectors, Plk3 overexpression and Plk3 knock down. Saos-2 cells exhibiting Plk3 overexpression demonstrated marked growth inhibition, while the Plk3 knockdown vector (shPlk3#2) revealed evident growth promotion, when compared with the untreated group (Fig. 3A). In addition, a colony formation assay was used (Fig. 3B). The average number of colonies in the control group was standardized to 1. The data are presented as the fold change over vector for a better comparison. The number of colonies in the Plk3 overexpression group was found to be 35.3% compared with the control group. The shPlk3#2 group was 3.48 fold greater than the control group. (P<0.05). The data indicated there was a significant increase in colony formation as a result of the low expression of Plk3 (Fig. 3C). An EdU assay using U2OS cell lines further demonstrated the function of Plk3 in proliferation, in vitro. When Plk3 was over expressed by the transfected recombinant plasmid, or knocked down by the shRNA, a similar tendency was detected (Fig. 4).

A previous study demonstrated that Ect2 promotes cell proliferation by regulating p21, a cell cycle-related gene, which is required for Rb protein-mediated G₁ arrest (31). To further investigate the in vivo interaction between Plk3 and p21, total proteins from Saos-2 cells were extracted and co-IP experiments were performed. IP was performed with antibodies against p21 followed by IB with antibodies against Plk3 (Fig. 5A, left panel). Simultaneously, IP was performed with antibodies against Plk3 followed by IB with antibodies against p21 (Fig. 5A, right panel). The co-IP assay indicated that P21 was physically associated with Plk3 in vivo. To consider the role of p21 in OS, the effects of Plk3 on the expression levels of p21 were examined. The results revealed that protein levels of p21 increased in Saos-2 cells that had been transfected with Plk3 when compared with the control cells (Fig. 5B, left panel). When Plk3 was knocked down, the protein levels of p21 decreased (Fig. 5B, right panel). These results indicate that Plk3 interacts with p21 and the p21 protein level changes along with the Plk3 level, indicating that Plk3 may cause post-translational modification regulation of the P21 protein level and p21 activity may lead to cell cycle arrest.